Clinical Trial Detail

NCT ID NCT02860000
Title Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Mayo Clinic
Indications

Her2-receptor negative breast cancer

Therapies

Alisertib + Fulvestrant

Alisertib

Age Groups: senior adult

Additional content available in CKB BOOST